1. Home
  2. CLVT
  3. Earnings

AI Earnings Predictions for Clarivate Plc (CLVT)

Machine learning predictions based on historical earnings data and price patterns

Latest Prediction

SELL

1-Day Prediction

-1.91%

$2.01

0% positive prob.

5-Day Prediction

-3.33%

$1.98

0% positive prob.

20-Day Prediction

+0.33%

$2.06

0% positive prob.

Price at prediction: $2.05 Confidence: 100.0% Model AUC: 1.0000 Quarter: Q3 2026

Historical Earnings Predictions

Quarter Signal 1D Return 5D Return 20D Return Confidence Actual 5D
Q3 2026 SELL -1.91% -3.33% +0.33% 100.0% Pending
Q2 2026 BUY -1.28% +7.01% +4.15% 100.0% -9.77%

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K SELL

Nov 3, 2026 · 100% conf.

AI Prediction SELL

1D

-1.91%

$2.01

Act: +1.44%

5D

-3.33%

$1.98

20D

+0.33%

$2.06

Price: $2.05 Prob +5D: 0% AUC: 1.000
0001764046-26-000125

EX-99.1

2 ex991q32026earningsrelease.htm

EX-99.1

Ex. 99.1 Q3 2026 Earnings Release

1

Clarivate Reports Third Quarter 2026 Results, Delivering Clear Path to Value Creation

— Improved recurring organic revenue growth driven by portfolio transformation

and AI-led innovation —

— Updates 2026 financial outlook following the divestiture of Life Sciences & Healthcare segment —

London, UK -- November 3, 2026 Clarivate Plc (NYSE: CLVT) (the “Company” or “Clarivate”), a leading

global provider of transformative intelligence, today reported results for the third quarter ended September 30,

2026.

Executive Commentary

Matti Shem Tov, Chief Executive Officer:

“Third quarter results continued to improve across key metrics, including organic recurring revenue growth and

the return to positive ACV growth in the Intellectual Property segment. We also achieved a major milestone with

the early close of the Life Sciences & Healthcare segment divestiture, positioning us for enhanced value creation

in our two market-leading segments, Academia & Government and Intellectual Property. The growing

commercial traction and customer validation from our AI-led innovation within A&G and IP give us confidence

in our ability to deliver on our commitments of accelerating sustained organic growth, expanding free cash flow

and reducing leverage.”

Michael Easton, Executive Vice President and Chief Financial Officer:

“We are seeing the benefits of disciplined execution across the business, with improving growth trends, strong

margins and continued free cash flow generation. Our focus remains on translating organic growth into

sustainable earnings and free cash flow, while maintaining a disciplined approach to capital allocation. Looking

ahead, we are well positioned to further strengthen our financial profile and enhance our financial flexibility.”

Third Quarter 2026 Results

Total revenues were $567.9 million, including the Life Sciences & Healthcare segment (“LS&H”), which was

divested on October 6, 2026, compared to total revenues of $623.1 million for the third quarter of 2025, primarily

due to inorganic disposals. Excluding LS&H, which is now presented as discontinued operations, total

revenues were $481.6 million, compared to total revenues of $530.3 million for the third quarter of 2025,

primarily due to inorganic disposals.

Organic revenues for continuing operations increased 0.4% as organic subscription growth of 1.5% and organic

re-occurring growth of 0.7% was partially offset by lower organic transactional revenues.

Organic ACV for continuing operations grew 1.8% compared to September 30, 2025, reflecting continued

progress toward a more sustainable, subscription-led revenue base.

Net loss, including LS&H, was $80.8 million, or $0.13 per diluted share, compared to a net loss of $28.3 million,

or $0.04 per diluted share, for the third quarter of 2025, driven by a $62.2 million non-cash LS&H goodwill

impairment charge. Adjusted net income, including LS&H, was $136.0 million, or $0.21 per diluted share,

compared to $119.3 million, or $0.18 per diluted share, for the third quarter of 2025. Adjusted EBITDA,

including LS&H, was $245.3 million, compared to Adjusted EBITDA of $252.4 million for the third quarter of

2025.

First Nine Months 2026 Results

Total revenues were $1,740.7 million, including the LS&H segment, compared to total revenues of $1,838.2

million, primarily due to inorganic disposals. Excluding the LS&H segment, which is now presented as

discontinued operations, total revenues were $1,472.4 million, compared to total revenues of $1,546.7 million

for the first nine months of 2025, primarily due to inorganic disposals.

Organic revenues for continuing operations increased 0.1%, as a 0.9% increase in organic recurring revenues

(subscription and re-occurring) was offset by lower organic transactional revenues.

2

Net loss, including LS&H, was $389.6 million, or $0.61 per diluted share, compared to a net loss of $204.2

million, or $0.30 per diluted share, for the first nine months of 2025, driven by a $283.9 million non-cash LS&H

goodwill impairment charge. Adjusted net income, including LS&H, was $378.4 million, or $0.59 per diluted

share, compared to $338.4 million, or $0.49 per diluted share, for the first nine months of 2025. Adjusted

EBITDA, including LS&H, was $733.7 million, compared to Adjusted EBITDA of $747.2 million for the first

nine months of 2025.

Clarivate, including LS&H, generated $399.0 million of operating cash flow and $233.1 million of free cash flow

during the first nine months of 2026.

Selected Financial Information

(In millions, except percentages and per share data),

(unaudited)

Three Months Ended

September 30,

Change

Nine Months Ended

September 30,

Change

2026

2025

$

%

2026

2025

$

%

Revenues, including discontinued operations

$567.9

$623.1

$(55.2)

(8.9)%

$1,740.7

$1,838.2

$(97.5)

(5.3)%

Revenues, continuing operations

$481.6

$

2026
Q2

Q2 2026 Earnings

8-K BUY

Jul 29, 2026 · 100% conf.

AI Prediction BUY

1D

-1.28%

$2.12

Act: -6.51%

5D

+7.01%

$2.30

Act: -9.77%

20D

+4.15%

$2.24

Price: $2.15 Prob +5D: 100% AUC: 1.000
0001764046-26-000090

Transcript text not available. View on SEC.gov →

2026
Q1

Q1 2026 Earnings

8-K

Apr 29, 2026

0001764046-26-000057

Transcript text not available. View on SEC.gov →

About Clarivate Plc (CLVT) Earnings

This page provides Clarivate Plc (CLVT) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.

Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on CLVT's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.

Share on Social Networks: